Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
|Videos|September 19, 2016
The Status of Biomarker Research in Low-Grade Gliomas
Author(s)Erica Bell, PhD
Erica Bell, PhD, assistant professor, radiation oncology, Ohio State University Comprehensive Cancer Center, discusses the status of biomarker research in low-grade gliomas.
Advertisement
Advertisement
Related to this article
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival with standard of care in glioblastoma but showed benefit in patients 65 years and younger.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
4
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
5